A phase IV open label randomised controlled trial of rituximab in induction therapy for living donor renal transplantation.
Phase of Trial: Phase IV
Latest Information Update: 28 Jan 2016
At a glance
- Drugs Rituximab (Primary) ; Hydrocortisone; Mycophenolate mofetil; Prednisolone; Tacrolimus
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Acronyms ReMIND; RituxiRT
- 28 Jan 2016 According to the United Kingdom Clinical Research Network record, status changed from recruiting to suspended.
- 18 Nov 2015 Accrual to date is 24% according to United Kingdom Clinical Research Network.
- 07 Oct 2015 Accrual to date is 23% according to United Kingdom Clinical Research Network.